Dr. Maria Isabel Achatz led a recent publication on the cost-effectiveness of Cancer surveillance for patients with LFS in Brazil using the Toronto Protocol screening guidelines. Brazil has a higher prevalence of LFS compared to other countries, due to a founder mutation in the TP53 gene.
